Akebia Secures $55 Million Term Loan Financing
Strengthens Balance Sheet Ahead of Potential Vadadustat Approval on March 27, 2024 CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical comp...
- Supported exchanges /
- F /
- AX9.F
Akebia Therapeutics Inc (AX9 F) stock market data APIs
€1.531
0(0%)
as of November 1, 2024
Price chart is built with Anychart
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Akebia Therapeutics Inc Financial Data Overview
| 1.531 | |
| 1.531 | |
| - | |
| 1.531 | |
| 1.531 | |
| 0.778-2.85 | |
| 330 M | |
| 210 M | |
| 174 M | |
| 0.762 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'AX9',
Type:
'Common Stock',
Name:
'Akebia Therapeutics Inc',
Exchange:
'F',
CurrencyCode:
'EUR',
CurrencyName:
'Euro',
CurrencySymbol:
'€',
CountryName:
'Germany',
CountryISO:
'DE',
OpenFigi:
NULL,
ISIN:
NULL,
CIK:
NULL,
EmployerIdNumber:
NULL,
FiscalYearEnd:
'December',
IPODate:
NULL,
InternationalDomestic:
NULL,
Sector:
'Healthcare',
Industry:
'Drug Manufacturers - Specialty & Generic',
CUSIP:
NULL,
}
Akebia Therapeutics Inc Fundamental Data is available in our Financial Data APIs
- Net Revenue 174 M
- EBITDA 4 081 K
- Earnings Per Share -0.19
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Akebia Therapeutics Inc Earnings via APIs
- Latest Release 2024-11-06
- EPS/Forecast NaN
Get Akebia Therapeutics Inc End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Akebia Therapeutics Inc latest news via APIs
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer
CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ...
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
